94 related articles for article (PubMed ID: 1746976)
1. [Effects of urinastatin on prevention of cisplatin induced nephrotoxicity].
Sasa H; Hisano A; Kudo K; Kuki E; Miyauchi M; Kita T; Kikuchi Y; Tode T; Furuya K; Nagata I
Gan To Kagaku Ryoho; 1991 Dec; 18(15):2623-5. PubMed ID: 1746976
[No Abstract] [Full Text] [Related]
2. [Preventive effect of urinastatin on cisplatin-induced nephrotoxicity].
Kobayashi H; Ishizuka H; Hirashima Y; Ohi H; Demukai H; Moniwa M; Maeda M; Kobayashi T; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1959-64. PubMed ID: 2592819
[TBL] [Abstract][Full Text] [Related]
3. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
4. Use of cis-platinum in the treatment of ovarian carcinoma. Clinical results and evaluation of nephrotoxicity.
Giannattasio M; Rizzi R; Coratelli P; Restaino A; Selvaggi L; Ferreri R; Orlando E; Ierardi GM; Granata A; Bettocchi S
Eur J Gynaecol Oncol; 1983; 4(1):41-3. PubMed ID: 6407837
[No Abstract] [Full Text] [Related]
5. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
6. [An evaluation of two postoperative chemotherapy protocols in ovarian common epithelial cancer: a comparison of continuous and intermittent hospitalization].
Sakamoto H; Suzuki H; Hayakawa S; Kiseki Y; Miyakawa Y; Ohkubo Y; Watanabe Y; Takami M; Kashiwazaki K; Tanaka H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1491-4. PubMed ID: 2584826
[No Abstract] [Full Text] [Related]
7. [The potentials of combined chemotherapy in disseminated ovarian cancer].
Gorbunova VA; Perevodchikova NI; Kozachenko VP; Ryzhakov VM; Marenich AF; Zhordania KI
Akush Ginekol (Mosk); 1991 Feb; (2):54-7. PubMed ID: 1907433
[No Abstract] [Full Text] [Related]
8. [Combined chemotherapy including platinum derivatives in the combined treatment of patients with stage-III to -IV ovarian cancer].
Perevodchikova NI; Gorbunova VA; Grigorova TM; Kozachenko VP; Marenich AF
Vestn Akad Med Nauk SSSR; 1986; (5):8-11. PubMed ID: 3755271
[No Abstract] [Full Text] [Related]
9. [Chemotherapy of ovarian tumors using cis-platin].
Laurová L; Kobilková J; Novotná J; Motlík K; Fricová M; Hornický J
Cesk Gynekol; 1987 Feb; 52(1):41-4. PubMed ID: 3568161
[No Abstract] [Full Text] [Related]
10. [Evaluation of the renal function in patients with ovarian carcinoma subjected to polychemotherapy including cisplatin or carboplatin].
Gadducci A; Facchini V; Dell'Arciprete T; Del Bravo B; Galigani P; Palla R; Fioretti P
Minerva Ginecol; 1988 Jan; 40(1):33-8. PubMed ID: 3287233
[No Abstract] [Full Text] [Related]
11. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
Omura GA; Brady MF
Obstet Gynecol; 1993 Apr; 81(4):641-2. PubMed ID: 8459984
[No Abstract] [Full Text] [Related]
12. [Use of metoclopramide and dexamethasone in preventing vomiting associated with antineoplastic chemotherapy].
Sobkowski W; Jassem J
Pol Tyg Lek; 1987 Jul 6-7; 42(27-28):841-3. PubMed ID: 3684761
[No Abstract] [Full Text] [Related]
13. [Clinical study of combination chemotherapy with CDDP, ADM and CPM for ovarian cancer].
Kobayashi H; Maeda M; Hayata T; Kawashima Y
Nihon Gan Chiryo Gakkai Shi; 1988 Apr; 23(4):829-36. PubMed ID: 3204307
[No Abstract] [Full Text] [Related]
14. [Comparative research on different treatment regimens in disseminated cancer of the ovaries].
Marinov L; Koĭnov K; Tsekova V; Velikova M
Akush Ginekol (Sofiia); 1987; 26(1):49-52. PubMed ID: 3592111
[No Abstract] [Full Text] [Related]
15. [Tumor chemotherapy of ovarian cancer patients in advanced age].
Behling H; Schirmer A; Krafft W; Brückmann D
Zentralbl Gynakol; 1988; 110(2):95-101. PubMed ID: 3364065
[TBL] [Abstract][Full Text] [Related]
16. Advanced ovarian carcinoma: a pilot study of cis-dichlorodiammineplatinum(II) in combination with adriamycin and cyclophosphamide in previously untreated patients and as a single agent in previously treated patients.
Williams CJ; Stevenson KE; Buchanan RB; Whitehouse JM
Cancer Treat Rep; 1979; 63(11-12):1745-53. PubMed ID: 393378
[No Abstract] [Full Text] [Related]
17. [Treatment of advanced ovarian carcinoma with cyclophosphamide, adriamycin and cisplatin: evaluation of the therapeutic response and analysis of the collateral effects].
Facchini V; Gadducci A; Ceccarelli P; Dell'Arciprete T; Del Bravo B; Bartolini T; Fioretti P
Ann Ostet Ginecol Med Perinat; 1986; 107(6):359-68. PubMed ID: 3566043
[No Abstract] [Full Text] [Related]
18. Cisplatin, doxorubicin, and cyclophosphamide (PAC) in the treatment of mixed mesodermal tumor of the ovary.
Wheelock J; Hancock K; Smith K
Cancer Treat Rep; 1987 Dec; 71(12):1275-6. PubMed ID: 3690537
[No Abstract] [Full Text] [Related]
19. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
Ehrlich CE; Einhorn L; Williams SD; Morgan J
Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134
[No Abstract] [Full Text] [Related]
20. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
